Piramal Pharma Limited (NSE:PPLPHARMA)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Pharma	91.51B	81.71B	70.82B	67.34B	58.87B
Pharma Growth	11.99%	15.39%	5.16%	14.39%	-
Total	91.51B	81.71B	70.82B	67.34B	58.87B
Total Growth	11.99%	15.39%	5.16%	14.39%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
outside India	74.89B	65.08B	56.37B	53.34B	50.14B
outside India Growth	15.07%	15.45%	5.69%	6.37%	-
India	16.62B	16.63B	14.44B	12.26B	8.15B
India Growth	-0.06%	15.14%	17.86%	50.42%	-
Total	91.51B	81.71B	70.82B	65.59B	58.29B
Total Growth	11.99%	15.39%	7.97%	12.52%	-

Source: S&P Global Market Intelligence.